SUPPLEMENTAL DIGITAL CONTENT

Meaningful Improvement and Worsening in Patients who do not Achieve Low Disease Activity and Switch Therapy to a New Biologic or Targeted Disease-modifying Anti-Rheumatic Drug: Results from the CorEvitas RA Registry

Table, Supplemental Digital Content 1. Outcomes and time-variant clinical characteristics at each visit for switchers

Characteristic	$V_{Pre\text{-}BL}$ (N^a = 93)	V_{BL} (N^a = 93)	$V_{F/U}$ (N^a = 93)
CDAI, mean (SD)	32.6 (12.7)	22.2 (10.8)	20.5 (13.5)
CDAI category, n (%)			
Remission (CDAI <2.8)	N/A	N/A	<5
Low (2.8≤ CDAI <10)	N/A	N/A	18 (19.4)
Moderate (10≤ CDAI <22)	12 (12.9)	60 (64.5)	33 (35.5)
High (CDAI ≥22)	81 (87.1)	33 (35.5)	38 (40.9)
TJC, mean (SD)	12.2 (7.8)	7.1 (6.7)	7.0 (6.7)
SJC, mean (SD)	8.6 (6.2)	5.3 (4.7)	5.3 (5.5)
TJC (28) – SJC (28), mean (SD)	3.6 (8.2)	1.8 (6.8)	1.8 (5.6)
SJC/TJC[b], mean (SD)	1.2 (2.1)	1.1 (1.1)	0.9 (1.0)
TJC-SJC ≥7, n (%)	30 (32.3)	15 (16.1)	17 (18.3)
SJC/TJC <0.5[b], n (%)	25 (26.9)	26 (28.0)	28 (30.1)
Physician-reported global assessment, mean (SD)	52.7 (20.7)	41.2 (22.1)	33.5 (22.6)
Patient-reported global assessment, mean (SD)	66.1 (19.7)	56.6 (22.1)	48.2 (24.6)
HAQ, mean (SD)	1.3 (0.7)	1.3 (0.7)	1.2 (0.7)
Patient-reported pain, mean (SD)	70.1 (20.8)	60.5 (23.7)	53.9 (26.2)
Patient-reported fatigue, mean (SD)	67.1 (26.5)	63.9 (29.6)	57.7 (28.4)
Morning stiffness, n (%)	87 (93.5)	87 (93.5)	82 (89.1)
Morning stiffness duration (h), mean (SD)	3.0 (4.4)	2.7 (4.8)	2.3 (4.4)
Current prednisone use, n (%)			
Not using	55 (59.1)	49 (52.7)	60 (64.5)
Current use, missing dose	<5	<5	<5
Dose <10 mg daily	22 (23.7)	27 (29.0)	23 (24.7)
Dose ≥10 mg daily	13 (14.0)	17 (18.3)	10 (10.8)
Treatment modifications[c]			
Prednisone added, n (%)	-	13 (14.0)	-
Prednisone stopped, n (%)	-	7 (7.5)	-
Prednisone dose increased by 5+ mg, n (%)	-	<5	-
MTX use, n (%)	-	42 (45.2)	-
MTX added, n (%)	-	<5	-
MTX stopped, n (%)	-	<5	-
MTX dose increased by 5+ mg, n (%)	-	<5	-
csDMARD use – not including MTX, n (%)	-	29 (31.2)	-
csDMARD started – not including MTX, n (%)	-	7 (7.5)	-
csDMARD stopped – not including MTX, n (%)	-	7 (7.5)	-
csDMARD use, n (%)	-	64 (68.8)	-

csDMARD added, n (%)	-	9 (9.7)	-
csDMARD stopped, n (%)	-	11 (11.8)	-
Biologic dose increased, n (%)	-	<5	-
Biologic dose decreased, n (%)	-	<5	-
Corticosteroid injection, n (%)	-	<5	-

[a]N refers to initiation episodes; a total of 87 patients contributed 1 initiation and 3 patients contributed 2 initiations each to the cohort. [b]Among those reporting TJC > 0. [c]Treatment modifications were identified only at V_{BL}, at or prior to the switch.

CDAI, clinical disease activity index; csDMARDs, conventional disease modifying anti-rheumatic drugs; IL-6, interleukin-6; HAQ, health assessment questionnaire; JAKi, Janus kinase inhibitor; MTX, methotrexate; N/A, not applicable, indicates zero count by cohort definition; SD, standard deviation; SJC, swollen joint counts; TJC, tender joint counts; $V_{Pre\text{-}BL}$, index visit; V_{BL}, baseline visit; V_{FU}, follow-up visit.

7